Line 262: | Line 262: | ||
</div> | </div> | ||
− | <div class="block | + | <div class="block full"> |
<div class="legend"><b>Figure 15: </b> <b>(A)</b> Percentage area of <FONT face="raleway">β</FONT>-III Tubulin in each well and <b>(B)</b> number of stained nuclei in each well with no NGF, 50 ng/mL, 250 ng/mL, 500 ng/mL, 750 ng/mL and 900 ng/mL of commercial NGF added in our medium Neurobasal, B27, GlutaMAX. Each condition was compared to the control group without NGF. <i>(ns: non-significant, *: p<0.05, **: p<0.01, ***: p<0.001, ****: p<0.0001).</i></div> | <div class="legend"><b>Figure 15: </b> <b>(A)</b> Percentage area of <FONT face="raleway">β</FONT>-III Tubulin in each well and <b>(B)</b> number of stained nuclei in each well with no NGF, 50 ng/mL, 250 ng/mL, 500 ng/mL, 750 ng/mL and 900 ng/mL of commercial NGF added in our medium Neurobasal, B27, GlutaMAX. Each condition was compared to the control group without NGF. <i>(ns: non-significant, *: p<0.05, **: p<0.01, ***: p<0.001, ****: p<0.0001).</i></div> | ||
</div> | </div> | ||
Line 273: | Line 273: | ||
</div> | </div> | ||
− | <div class="block | + | <div class="block full"> |
<div class="legend"><b>Figure 16:</b> Ratio of the percentage area of <FONT face="raleway">β</FONT>-III Tubulin on the number of stained nucleus. <i>(ns: non-significant, * : p<0.05, ** : p<0.01, *** : p<0.001, **** : p<0.0001).</i> </div> | <div class="legend"><b>Figure 16:</b> Ratio of the percentage area of <FONT face="raleway">β</FONT>-III Tubulin on the number of stained nucleus. <i>(ns: non-significant, * : p<0.05, ** : p<0.01, *** : p<0.001, **** : p<0.0001).</i> </div> | ||
Line 285: | Line 285: | ||
<p>After having collected the data on the effect of commercial NGF, we decided to put in culture our cells in the presence of our bacterial lysate to test the effect of our proNGF. We put in culture for 2 days 30 000 cells with or without commercial NGF at 500 ng/mL and 900 ng/mL as well as our bacterial lysate in different dilutions. Since we wanted to inactivate as much bacterial proteins as possible (Endotoxins), we checked the denaturation temperature for our proNGF, 70°C, and heat-inactivated the lysate at 60°C for 5 minutes before putting it in culture. Due to lack of time, only one well per condition was analyzed. </p> </div> | <p>After having collected the data on the effect of commercial NGF, we decided to put in culture our cells in the presence of our bacterial lysate to test the effect of our proNGF. We put in culture for 2 days 30 000 cells with or without commercial NGF at 500 ng/mL and 900 ng/mL as well as our bacterial lysate in different dilutions. Since we wanted to inactivate as much bacterial proteins as possible (Endotoxins), we checked the denaturation temperature for our proNGF, 70°C, and heat-inactivated the lysate at 60°C for 5 minutes before putting it in culture. Due to lack of time, only one well per condition was analyzed. </p> </div> | ||
− | <div class="block | + | <div class="block full"> |
<div class="legend"><b> Figure 17:</b> (A) Percentage area of <FONT face="raleway">β</FONT>-III Tubulin in each well and (left) percentage area of nucleus in each well with no commercial NGF, 500 ng/mL or 900 ng/mL or bacterial lysate at 1/5, 1/10, 1/20 or 1/30 added in our medium Neurobasal, B27, GlutaMAX. </div> | <div class="legend"><b> Figure 17:</b> (A) Percentage area of <FONT face="raleway">β</FONT>-III Tubulin in each well and (left) percentage area of nucleus in each well with no commercial NGF, 500 ng/mL or 900 ng/mL or bacterial lysate at 1/5, 1/10, 1/20 or 1/30 added in our medium Neurobasal, B27, GlutaMAX. </div> | ||
Line 298: | Line 298: | ||
</div> | </div> | ||
− | <div class="block | + | <div class="block full"> |
<div class="legend"><b>Figure 18: </b> Image of the whole well of the 96-well plate. Neurons were put in culture in Neurobasal, B27, GlutaMAX, and our lysate at a concentration of 1/10 medium.</div> | <div class="legend"><b>Figure 18: </b> Image of the whole well of the 96-well plate. Neurons were put in culture in Neurobasal, B27, GlutaMAX, and our lysate at a concentration of 1/10 medium.</div> | ||
</div> | </div> |
Revision as of 01:39, 18 October 2018
RECONNECT NERVES: DNA ASSEMBLY
Click to see more
Summary
Achievements:
- Successfully cloned a biobrick coding for secretion of NGF in pET43.1a and iGEM plasmid backbone pSB1C3, creating a new part BBa_K2616000.
- Successfully sequenced BBa_K2616000 in pSB1C3 and sent to iGEM registry.
- Successfully co-transformed E. coli with plasmid secreting proNGF and plasmid expressing the secretion system, creating bacteria capable of secreting NGF in the medium.
- Successfully characterized production of proNGF thanks to mass spectrometry and western blot.
- Successfully observed axon growth in microfluidic chip in presence of commercial NGF.
- Successfully observed activity of our proNGF in invitro cellular culture compared to commercial NGF with a concentration between 500 ng/mL and 900 ng/mL.
Next steps:
- Purify secreted proNGF, and characterize its effects on neuron growth thanks to our microfluidic device.
- Global proof of concept in a microfluidic device containing neurons in one of the chamber, and our engineered bacteria in the other.
CELL CULTURE
Click to see more
FIGHT INFECTIONS
Click to see more
Summary
Achievements:
- Successfully cloned a biobrick coding for RIP secretion in pBR322 and in pSB1C3, creating a new part Bba_K2616001 .
- Successfully sequenced Bba_K2616001 in pSB1C3 and sent to iGEM registry.
- Successfully cultivated S. aureus biofilms in 96-well plates with different supernatants. Although there was a high variability in our results, and we used several protocols to overcome it, in one case, we were able to observe a reduction in biofilm formation in the presence of our RIP.
Next steps:
- Clone the sensor device with inducible RIP production upon S. aureus detection.
- Improve the characterization of RIP effect on biofilm formation with a more standardized assay.
KILL SWITCH
Click to see more
Summary
Achievements:
- Successfully cloned the biobrick Bba_K2616002 coding for toxin/antitoxin (CcdB/CcdA) system in pSB1C3, creating a new part.
- Successfully sequenced BBa_K2616002 in pSB1C3 and sent it to iGEM registry.
- Successfully observed normal growth of our engineered bacteria at 25°C and 37°C and absence of growth at 18°C and 20°C, showing the efficiency of the kill switch.
Next steps:
- Find a system that kills bacteria when released in the environment rather than just stopping their growth.
MEMBRANE
Click to see more
Summary
Achievements:
- Successfully demonstrated the confinement of bacteria by a membrane filter
- Successfully coated alumina oxide membranes with PEDOT:Cl and PEDOT:Ts
- Partially coated alumina oxide membranes with PEDOT:PSS
- Successfully demonstrated the enhanced conductivity induced by the PEDOT:Cl and PEDOT:Ts coating
- Successfully enhanced biocompatibilty with PEDOT:Cl coating
Next steps:
- Enhance measurement precision for membrane conductivity with and without biofilm
- Improve PEDOT:PSS coating to form a uniform layer